BioNTech returns to cancer roots with deal for Gilead cell therapy factory

BioNTech, the German drug developer now best known for the coronavirus vaccine it developed in partnership with Pfizer, will buy a cancer cell therapy factory and related research from Gilead's Kite Pharma unit.